Hairy Cell Leukemia with Unusual Clinical Presentations: A Single Center Experience

Abdulkadir Basturk¹, Sema Akinci¹, Tuba Hacibekiroglu¹, Tekin Guney¹, Sule MB Ozturk¹, Ali Kutlucan², Imdat Dilek¹

¹Ataturk Research and Training Hospital, Ankara, Turkey
²Selcuklu University, Konya, Turkey

In this study we report 10 cases of hairy cell leukemias (HCL). Some of them were presented with atypical and rare clinical presentations: One of them was presented with ascites, another case was presented with intramuscular hematoma and four cases were presented with no splenomegaly. From 2009 to 2013, HCL diagnosed in 10 of 186 (5.3%) acute and chronic leukemias and they were included in this study. Eight patients were treated with cladribin with 87.5% complete response and 12.5% partial response rate. One patient was treated only with palliative radiotherapy. One patient was treated in another hospital after diagnosis.

Key words: Hairy cell leukemia, lymphoproliferative disorder, ascites, atypical presentation

Corresponding author: Abdulkadir Basturk, MD, Division of Hematology, Department of Internal Medicine, Ataturk Research and Training Hospital, Lodumlu, Bilkent 06800, Ankara, Turkey. Tel:+905307461629, E-mail: drbasturk@yandex.com.
INTRODUCTION

Hairy cell leukemia (HCL) is a rare chronic clonal B-cell lymphoproliferative disorder [1]. The cause of HCL is not known but the morphologic findings, clinical manifestations, and pathologic features are well described. HCL is generally characterized by splenomegaly, pancytopenia, and infiltration of the bone marrow with lymphocytes which have irregular cytoplasmic projections [2] (figure 1).

The hairy cells show expression of pan B cell surface antigens (CD19, CD20, and CD22) and also express surface antigens such as CD11c, CD25 and CD103 which are not common on B cells normally [3,4]. Most patients have few symptoms at diagnosis but some patients may have serious pancytopenia, symptomatic splenomegaly or constitutional symptoms. These serious symptoms require treatment [5]. In treatment of HCL, the purine analogs cladribine or pentostatin is the first choice of treatment [6]. In this study we report ten cases of hairy cell leukemia; some with atypical and rare presentations.

CASE SERIES

From 2009 to 2013, HCL diagnosed in 10 of 186 (5.3%) acute and chronic leukemias and they were included in this study. HCL diagnosis was established by bone marrow biopsy, peripheral blood flowcytometry and tartrate-resistant acid phosphatase staining (TRAP, figure 2).

Assessment of remission was performed with bone marrow biopsy at the end of 3 months of treatment. Mean follow up time was 14.7 months. Seven of the 10 cases received cladribine (0.1 mg/kg, 7 days continue infusion) as a first line treatment. And the 8th case received cladribine as a second line treatment after rituximab. The 1st case received only palliative radiotherapy to spleen and supportive treatment because of low performance status. The 10th case was treated in another hospital after diagnosis. Demographic and laboratory findings of patients are shown in table 1 and detailed diagnostic tools are shown in table 2.

Table 1 – Laboratory and clinical findings, response situation and follow up of 10 HCL patients

<table>
<thead>
<tr>
<th>Case</th>
<th>Gender</th>
<th>Age</th>
<th>Wbc (x10⁹/L); neu (x10⁹/L); hgb (g/dL); plt (x10⁹/L)</th>
<th>Spleen (below the left costal margin)</th>
<th>Treatment</th>
<th>Retikulin rate</th>
<th>Response situation and follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>female</td>
<td>85</td>
<td>3.3/1.4/10.4/83</td>
<td>20 cm</td>
<td>Palliative RT</td>
<td>Grade I</td>
<td>On 4. month: exitus</td>
</tr>
<tr>
<td>2</td>
<td>female</td>
<td>80</td>
<td>18/1.0/6.4/49</td>
<td>normal</td>
<td>Cladribin</td>
<td>Grade II</td>
<td>On 16. month: in remission</td>
</tr>
<tr>
<td>3</td>
<td>female</td>
<td>72</td>
<td>44/3.4/11.9/151</td>
<td>12 cm</td>
<td>Cladribin</td>
<td>Grade II</td>
<td>On 11. month: in remission</td>
</tr>
<tr>
<td>4</td>
<td>female</td>
<td>45</td>
<td>1.1/0.1/8.3/110</td>
<td>normal</td>
<td>Cladribin</td>
<td>Grade III</td>
<td>On 17. month: in remission</td>
</tr>
<tr>
<td>5</td>
<td>male</td>
<td>51</td>
<td>3.5/0.5/6.4/43</td>
<td>15 cm</td>
<td>Cladribin</td>
<td>Grade III</td>
<td>On 19. month: in remission</td>
</tr>
<tr>
<td>6</td>
<td>male</td>
<td>59</td>
<td>2.5/1.0/8.4/59</td>
<td>normal</td>
<td>Cladribin</td>
<td>Grade III</td>
<td>On 19. month: in remission</td>
</tr>
<tr>
<td>7</td>
<td>male</td>
<td>57</td>
<td>3.1/0.9/4.6/76</td>
<td>25 cm</td>
<td>Cladribin</td>
<td>unknown</td>
<td>On 28. day: exitus</td>
</tr>
<tr>
<td>8</td>
<td>male</td>
<td>80</td>
<td>1.7/0.5/4.6/37</td>
<td>10 cm</td>
<td>Rituximab + Cladribin</td>
<td>Grade II</td>
<td>On 10. Month (after cladribine): in remission</td>
</tr>
<tr>
<td>9</td>
<td>male</td>
<td>42</td>
<td>2.8/0.75/14.4/57</td>
<td>normal</td>
<td>Cladribin</td>
<td>unknown</td>
<td>On 9. Month : in remission</td>
</tr>
<tr>
<td>10</td>
<td>male</td>
<td>31</td>
<td>1.7/0.2/7.36</td>
<td>12 cm</td>
<td>*</td>
<td>unknown</td>
<td>*</td>
</tr>
</tbody>
</table>

*He received treatment in another hospital after diagnosis
In a total of 10 cases (female: 4, male: 6) mean age was 60.2 (range 31-85). Splenomegaly was not present in four cases (40%), pancytopenia was not present in three cases (30%). One case presented with ascites (case 5) and one case presented with intramuscular hematoma (case 10). Among the 8 patients received cladribine, complete remission was achieved in 7 patients (87.5%). The seventh case, who had been given multiple chemotherapy before, died due to sepsis in the first month of the cladribin treatment. Although the symptoms were controlled and the spleen size was decreased in the patient who received only palliative radiotherapy, she died because of sepsis due to acute cholecystitis on the 4th month of the treatment. Response situations are shown in table-1.

### Discussion

Hairy cell leukemia is known as a rare B-cell lymphoproliferative disorder. It constitutes 2% of all leukemias and occurs more frequently in men (male/female ratio is 4:1) [7]. Similarly male to female ratio was 3/2 in our cases with male predominance. Rate of HCL among all leukemias was %5.3 in our patients.

Hairy cell leukemia may present with different clinical symptoms. While some of HCL patients are presenting with abdominal fullness or discomfort due to splenomegaly, others may present with systemic complaints such as fatigue, weakness, and weight loss [8]. In literature it was reported that leucocytosis is seen in 20% of HCL patients [9]. Similarly two of our patients had leucocytosis initially. Although splenomegaly is a nearly constant feature in the literature, four out of ten patients were found not to have palpable splenomegaly. As with our patients, less marked splenomegaly at presentation is probably due to early diagnosis of HCL.

In some patients clinical presentation may be atypical and diagnosis may be difficult. Some of our HCL patients had different complaints for many years. For example seventh case has been diagnosed as CLL in 2001 and has been treated with cladribine and in second line with fludarabine, cyclophosphamide and rituximab. However, HCL diagnosis was made in 2011. Similarly 4th case was investigated for more than one year because of neutropenia and finally she was diagnosed as HCL. The third case who was diagnosed marginal zone lymphoma at another center was reevaluated and had the diagnosis of HCL.

Cutaneous vasculitis, leukocytoclastic angiitis, erythema nodosum, pulmonary infiltrates, polyarthritis, or Raynaud phenomenon are unusual clinical manifestations of HCL [10,11]. In addition, pleural or ascitic fluid may be seen rarely and result from hairy cell involvement of those serosal surfaces [11]. Similar to these rare findings, one of our cases (case 5) presented with...
ascites in addition to splenomegaly and pancytopenia. After chemotherapy, the ascites has been resolved.

Palpable lymphadenopathy is uncommon in HCL. However, as a result of the routine use of computerized tomogram in the evaluation of patients with lymphoproliferative disorders, significant deep lymphadenopathy has been found in up to one-third of patients with HCL [12]. One of our patients had a single superficial cervical lymphadenopathy and one had multiple deep lymphadenopathies.

Staining of the BM trephine biopsy generally shows a moderate to marked increase in reticulin fibers in HCL [2]. Similar to this data all of our cases showed grade II to III reticular fibrosis in bone marrow.

Cladribine is the first treatment choice for HCL. A single course of cladribine generally induces long-lasting complete responses in most of patients [13]. Goodman et al. reported the long-term follow up of 349 patients who had received cladribine and revealed 319 (91%) complete responses (CR) and 22 (7%) partial responses with the overall response rate of 98% [15]. Similarly in our study, 7 of 8 cases (87.5%) achieved CR with a single course of cladribin.

Because hairy cells express the B-cell antigen CD20, a chimeric humanized mouse anti-CD20 monoclonal antibody rituximab is an other therapeutic option. Rituximab may be used in HCL patients who relapse after cladribine therapy with a response duration of less than 18 months and who demonstrate a significantly hypoplastic marrow or a prior severe opportunistic infection [7]. The 8th case of our patients received six courses of rituximab as first line treatment because he could not take cladribine due to health insurance problem. Partial response was achieved after rituximab.

In conclusion, keeping in mind the possibility of unusual presentations, diagnosis of HCL must be considered when cytopenic patients present with ascites or other unexplained signs or symptoms with or without splenomegaly.

References